Intracellular delivery of an antisense oligonucleotide via endocytosis of a G protein-coupled receptor

Nucleic Acids Research

Volumn 38, Issue 19, 2010, Pages 6567-6576

  Ming, Xin ^a   Alam, Md Rowshon ^a   Fisher, Michael ^a   Yan, Yongjun ^b   Chen, Xiaoyuan ^b   Juliano, Rudolph L ^a  

^a University of North Carolina   (United States)

^b NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ANTISENSE OLIGONUCLEOTIDE; BOMBESIN; CLATHRIN; DYNAMIN; G PROTEIN COUPLED RECEPTOR; RAB PROTEIN; RAB7 PROTEIN; RAB9 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONJUGATION; CONTROLLED STUDY; ENDOCYTOSIS; ENDOSOME; INTRACELLULAR TRANSPORT; MEMBRANE VESICLE; PINOCYTOSIS; PRIORITY JOURNAL; TRANS GOLGI NETWORK;

CELL LINE, TUMOR; ENDOCYTOSIS; HUMANS; KINETICS; LUCIFERASES, FIREFLY; OLIGONUCLEOTIDES, ANTISENSE; RECEPTORS, BOMBESIN;

EID: 78049363846     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkq534     Document Type: Article

References (45)

1. Prakash,T.P. and Bhat,B. (2007) 2′-Modified oligonucleotides for antisense therapeutics. Curr. Top. Med. Chem., 7, 641-649.
2. Bennett,C.F. and Swayze,E.E. (2010) RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol., 50, 259-293.
3. Debart,F., Abes,S., Deglane,G., Moulton,H.M., Clair,P., Gait,M.J., Vasseur,J.J. and Lebleu,B. (2007) Chemical modifications to improve the cellular uptake of oligonucleotides. Curr. Top. Med. Chem., 7, 727-737.
4. Corey,D.R. (2007) Chemical modification: the key to clinical application of RNA interference? J. Clin. Invest., 117, 3615-3622.
5. McManus,M.T. and Sharp,P.A. (2002) Gene silencing in mammals by small interfering RNAs. Nat. Rev. Genet., 3, 737-747.
6. Castanotto,D. and Rossi,J.J. (2009) The promises and pitfalls of RNA-interference-based therapeutics. Nature, 457, 426-433.
7. Juliano,R., Bauman,J., Kang,H. and Ming,X. (2009) Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol. Pharm., 6, 686-695.
8. Whitehead,K.A., Langer,R. and Anderson,D.G. (2009) Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov., 8, 129-138.
9. Gao,K. and Huang,L. (2009) Nonviral methods for siRNA delivery. Mol. Pharm., 6, 651-658.
10. Wu,S.Y. and McMillan,N.A. (2009) Lipidic systems for in vivo siRNA delivery. AAPS J., 11, 639-652.
11. Zimmermann,T.S., Lee,A.C., Akinc,A., Bramlage,B., Bumcrot,D., Fedoruk,M.N., Harborth,J., Heyes,J.A., Jeffs,L.B., John,M. et al. (2006) RNAi-mediated gene silencing in non-human primates. Nature, 441, 111-114.
12. Frank-Kamenetsky,M., Grefhorst,A., Anderson,N.N., Racie,T.S., Bramlage,B., Akinc,A., Butler,D., Charisse,K., Dorkin,R., Fan,Y. et al. (2008) Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc. Natl Acad. Sci. USA, 105, 11915-11920.
13. Lv,H., Zhang,S., Wang,B., Cui,S. and Yan,J. (2006) Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control Release, 114, 100-109.
14. Juliano,R., Alam,M.R., Dixit,V. and Kang,H. (2008) Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res., 36, 4158-4171.
15. Alam,M.R., Dixit,V., Kang,H., Li,Z.B., Chen,X., Trejo,J., Fisher,M. and Juliano,R.L. (2008) Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis. Nucleic Acids Res., 36, 2764-2776.
16. Alam,M.R., Ming,X., Dixit,V., Fisher,M., Chen,X. and Juliano,R.L. (2010) The biological effect of an antisense oligonucleotide depends on its route of endocytosis and trafficking. Oligonucleotides, 20, 103-109.
17. Cesarone,G., Edupuganti,O.P., Chen,C.P. and Wickstrom,E. (2007) Insulin receptor substrate 1 knockdown in human MCF7 ER+breast cancer cells by nuclease-resistant IRS1 siRNA conjugated to a disulfide-bridged D-peptide analogue of insulin-like growth factor 1. Bioconjug. Chem., 18, 1831-1840.
18. Armbruster,B.N. and Roth,B.L. (2005) Mining the receptorome. J. Biol. Chem., 280, 5129-5132.
19. Gilman,A.G. (1995) Nobel lecture. G proteins and regulation of adenylyl cyclase. Biosci. Rep., 15, 65-97.
20. Drake,M.T., Shenoy,S.K. and Lefkowitz,R.J. (2006) Trafficking of G protein-coupled receptors. Circ. Res., 99, 570-582.
21. Gaborik,Z. and Hunyady,L. (2004) Intracellular trafficking of hormone receptors. Trends Endocrinol. Metab., 15, 286-293.
22. Hanyaloglu,A.C. and von Zastrow,M. (2008) Regulation of GPCRs by endocytic membrane trafficking and its potential implications. Annu. Rev. Pharmacol. Toxicol., 48, 537-568.
23. Wolfe,B.L. and Trejo,J. (2007) Clathrin-dependent mechanisms of G protein-coupled receptor endocytosis. Traffic, 8, 462-470.
24. Ananias,H.J., de Jong,I.J., Dierckx,R.A., van de Wiele,C., Helfrich,W. and Elsinga,P.H. (2008) Nuclear imaging of prostate cancer with gastrin-releasing-peptide-receptor targeted radiopharmaceuticals. Curr. Pharm. Des., 14, 3033-3047.
25. Cornelio,D.B., Roesler,R. and Schwartsmann,G. (2007) Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Ann. Oncol., 18, 1457-1466.
26. Jensen,R.T., Battey,J.F., Spindel,E.R. and Benya,R.V. (2008) International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol. Rev, 60, 1-42.
27. Smith,C.J., Volkert,W.A. and Hoffman,T.J. (2005) Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. Nucl. Med. Biol., 32, 733-740.
28. Engel,J.B., Schally,A.V., Dietl,J., Rieger,L. and Honig,A. (2007) Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones. Mol. Pharm., 4, 652-658.
29. Kang,S.H., Cho,M.J. and Kole,R. (1998) Up-regulation of luciferase gene expression with antisense oligonucleotides: implications and applications in functional assay development. Biochemistry, 37, 6235-6239.
30. Liu,Z., Yan,Y., Chin,F.T., Wang,F. and Chen,X. (2009) Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN. J. Med. Chem., 52, 425-432.
31. Khalil,I.A., Kogure,K., Akita,H. and Harashima,H. (2006) Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol. Rev., 58, 32-45.
32. Robinson,M.S. (1994) The role of clathrin, adaptors and dynamin in endocytosis. Curr. Opin. Cell Biol., 6, 538-544.
33. Stenmark,H. (2009) Rab GTPases as coordinators of vesicle traffic. Nat. Rev. Mol. Cell Biol., 10, 513-525.
34. Bucci,C., Lutcke,A., Steele-Mortimer,O., Olkkonen,V.M., Dupree,P., Chiariello,M., Bruni,C.B., Simons,K. and Zerial,M. (1995) Co-operative regulation of endocytosis by three Rab5 isoforms. FEBS Lett., 366, 65-71.
35. Ullrich,O., Reinsch,S., Urbe,S., Zerial,M. and Parton,R.G. (1996) Rab11 regulates recycling through the pericentriolar recycling endosome. J. Cell Biol., 135, 913-924.
36. Bucci,C., Thomsen,P., Nicoziani,P., McCarthy,J. and van Deurs,B. (2000) Rab7: a key to lysosome biogenesis. Mol. Biol. Cell., 11, 467-480.
37. Lombardi,D., Soldati,T., Riederer,M.A., Goda,Y., Zerial,M. and Pfeffer,S.R. (1993) Rab9 functions in transport between late endosomes and the trans golgi network. EMBO J., 12, 677-682.
38. Wu,X., Lee,V.C., Chevalier,E. and Hwang,S.T. (2009) Chemokine receptors as targets for cancer therapy. Curr. Pharm. Des., 15, 742-757.
39. Li,S., Huang,S. and Peng,S.B. (2005) Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression. Int. J. Oncol., 27, 1329-1339.
40. Zhang,X., Cai,W., Cao,F., Schreibmann,E., Wu,Y., Wu,J.C., Xing,L. and Chen,X. (2006) 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J. Nucl. Med., 47, 492-501.
41. Yang,Y.S., Zhang,X., Xiong,Z. and Chen,X. (2006) Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma. Nucl. Med. Biol., 33, 371-380.
42. Chen,X., Park,R., Hou,Y., Tohme,M., Shahinian,A.H., Bading,J.R. and Conti,P.S. (2004) microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. J. Nucl. Med., 45, 1390-1397.
43. Varvarigou,A., Bouziotis,P., Zikos,C., Scopinaro,F. and De Vincentis,G. (2004) Gastrin-releasing peptide (GRP) analogues for cancer imaging. Cancer Biother. Radiopharm., 19, 219-229.
44. Nagy,A. and Schally,A.V. (2005) Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a "smarter" chemotherapy. Curr. Pharm. Des., 11, 1167-1180.
45. Safavy,A., Bonner,J.A., Waksal,H.W., Buchsbaum,D.J., Gillespie,G.Y., Khazaeli,M.B., Arani,R., Chen,D.T., Carpenter,M. and Raisch,K.P. (2003) Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery. Bioconjugate Chem., 14, 302-310.